Up to 6 million-euro grant available; application deadline is April 1, 2014December 12, 2013—PHILADELPHIA — The American Association for Cancer Research (AACR) is now accepting applications for a Sta Op Tegen Kanker (“Stand Up To Cancer” in Dutch) Dream Team Translational Cancer Research Grant. This grant opportunity will offer up to 6 million euros (U.S. $8.25 million, at the current conversion rate) in research funding and is provided by Stand Up To Cancer (SU2C) and KWF Kankerbestrijding (the Dutch Cancer Society).
The grant provides four years of funding for a translational cancer research project that will address critical problems in patient care and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional team of expert investigators. Research projects must be designed to accelerate the application of new preventive, diagnostic, or therapeutic agents to the clinic, and may focus on particular organ sites or on specialized research areas.
Proposals for the Sta Op Tegen Kanker Dream Team Translational Cancer Research Grant should describe plans indicating how the work will be translated into the clinic. To maximize creativity, innovation, and collaboration, the projects should also span multiple disciplines and use modern biological tools to address research questions in a coordinated way.
The leader of each project must be from a research institute located in the Netherlands. Co-leaders can be from research institutes in any country. Each project must include at least two research institutes located in the Netherlands and at least one research institute outside the Netherlands. At least 50 percent of the grant funds must be allocated to research conducted in the Netherlands.
Since the launch of SU2C in 2008, the AACR has played an integral role as SU2C’s scientific partner by providing scientific leadership, expert peer review, and grants administration. To that end, the AACR will work closely with the Dutch Cancer Society on this project. A SU2C-KWF Joint Scientific Advisory Committee will conduct a unique, rapid, and rigorous evaluation of the applications via a multistep scientific review process and make recommendations on the final grant recipients. Arnold J. Levine, Ph.D., professor at the Institute for Advanced Study in Princeton, N.J. and at the Cancer Institute of New Jersey in New Brunswick, N.J., will serve as chairperson of the committee. He will be joined by three distinguished scientists—two from research institutes in the Netherlands, and one from a research institute outside the Netherlands.
• Proposals for Sta Op Tegen Kanker Dream Team Translational Cancer Research projects are due by April 1, 2014, via proposalCENTRAL at https://proposalcentral.altum.com.
• For general information on eligibility criteria, the application process, and other details about this Dream Team grant, visit http://www.AACR.org/SU2Cfunding. Inquiries may be directed to the Scientific Review and Grants Administration Department at 267-765-1049 or email@example.com.
The Sta Op Tegen Kanker Dream Team Translational Cancer Research Grant is scheduled to be announced in the fall of 2014.
This grant is supported with money raised in connection with the Dutch versions of SU2C’s televised fundraising events, broadcast in the Netherlands in cooperation with the Dutch Cancer Society.
# # #
About Stand Up To Cancer
Stand Up To Cancer (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a program of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization, was established in 2008 by film and media leaders who utilize the industry’s resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about progress being made in the fight against the disease. As SU2C’s scientific partner, the American Association for Cancer Research (AACR) and a Scientific Advisory Committee led by Nobel Laureate Phillip A. Sharp, Ph.D., conduct rigorous, competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress.
Current members of the SU2C Council of Founders and Advisors (CFA) include Talk Show Host, Journalist and well-known Cancer Advocate Katie Couric; Sherry Lansing, Chairperson of the Entertainment Industry Foundation’s Board of Directors and Founder of the Sherry Lansing Foundation; EIF President and CEO Lisa Paulsen; EIF Senior Vice President Kathleen Lobb; Rusty Robertson and Sue Schwartz of the Robertson Schwartz Agency; Pamela Oas Williams, President of Laura Ziskin Productions and Executive Producer of Stand Up To Cancer’s In-house Production Team, and Nonprofit Executive Ellen Ziffren. All current members of the CFA were co-producers of the 2012 televised special. The late co-founder Laura Ziskin executive produced both the Sept. 5, 2008, and Sept. 10, 2010, broadcasts. SU2C was formally launched on May 27, 2008. Sung Poblete, Ph.D., R.N., has served as SU2C’s president and CEO since 2011.
About the Dutch Cancer Society
The Dutch Cancer Society is a nationwide organization for cancer-related work in the Netherlands. We spend approximately 80 percent of our net budget to finance cancer research; 20 percent is spent to public awareness and information, prevention and patient support programs. The DCS’s headquarters is located in Amsterdam; our professional staff amount to 160 persons. Over 100,000 volunteers support the Dutch Cancer Society whether it comes to local or nation-wide fundraising, scientific or policy advice in several councils and committees. We could rely on nearly 1,600 local committees that organize our annual door-to-door knocking campaign to raise funds for the fight against cancer (annual revenue around €8 million). The Dutch Cancer Society is supported by almost one million donors.
The Dutch Cancer Society has been leading the fight against cancer ever since it was founded in 1949. Our goal is less cancer, more cure, and a better quality of life for cancer patients.
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s oldest and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 18,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit http://www.AACR.org. Follow the AACR on Twitter: @AACR. Follow the AACR on Facebook: http://www.facebook.com/aacr.org.
Stand Up To Cancer
Jane E. Rubinstein
The Dutch Cancer Society (KWF Kankerbestrijding)
+31 0 205700538
American Association for Cancer Research